Last reviewed · How we verify
NCT05530447
Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy
trial testing Samelisant in Narcolepsy. No longer available.
Quick facts
| Lead sponsor | Suven Life Sciences Limited |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Samelisant — full drug profile →
Conditions studied
- Narcolepsy — all drugs for Narcolepsy →
Sponsor
Suven Life Sciences Limited — full company profile →
Who can join
Adults 18 to 65, any sex, with Narcolepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is planned to provide expanded access treatment to subjects with narcolepsy who have completed the 2-week treatment phase and follow-up in study CTP2S13031H3 (NCT04072380), and in instances when the investigator as well as the subject believe that the benefits outweigh the risks to continue the treatment with SUVN-G3031.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05530447
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Narcolepsy
Currently open trials in the same condition.
- NCT06797284 — The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders · NA · recruiting
- NCT06586138 — Study of Psychological, Sociological and Professional Factors Associated With Maintenance of Wakefulness Test · recruiting
- NCT04806620 — Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research · recruiting
- NCT05615584 — Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence · NA · recruiting
- NCT06279247 — Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy · recruiting
Other Suven Life Sciences Limited trials
Trials by the same sponsor.
- NCT06836063 — Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients · Phase 2 · completed
- NCT06705088 — Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants · Phase 1 · completed
- NCT06126497 — Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients · Phase 2 · completed
- NCT04072380 — A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataple · Phase 2 · completed
- NCT03551288 — Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05530447 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suven Life Sciences Limited
- Last refreshed: 23 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05530447.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing